Table 1. 5-Aminosalicylic Acid Treatment.

Author (year)	Level of published evidence	No. of patients	Outcome
Sonta et al. (2000)4	Case report	1	Mesalazine demonstrated clinical efficacy on esophageal ulcers
Jung et al. (2012)2	Retrospective (single tertiary academic center)	143	• Clinical relapse: 32.2% (relapse rates: 1 yr, 8.1%; 3 yr, 22.6%; 5 yr, 31.2%; 10 yr, 46.7%)
			• Poor response to 5-ASA therapy: younger age <35 yr; CRP >1.5 mg/dL; DAIBD score ≥60
Hisamatsu et al. (2014)5	Japanese consensus statements	-	The optimal dose of 5-ASA for adult patients, 2.25–3.00 g/day. Sulfasalazine is also used, the optimal dose is 3–4 g/day.
Hatemi et al. (2016)3	Retrospective (multidisciplinary center)	16	10 of 16 patients (62.5%) achieved remission and did not relapse during the 89.3±64.5 mo

5-ASA, 5-aminosalicylic acid; DAIBD, disease activity index for intestinal Behçet's disease.